FY25 consensus $20.88. Raises FY25 revenue view to $35B-$36B from $34.3B-$35.7B, consensus $35.34B. This guidance includes the estimated impact of implemented tariffs, but does not account for any tariffs or potential pricing actions announced or described but not implemented as well as any tariffs, sector specific tariffs, or pricing actions that could be implemented in the future.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Notable companies reporting after market close
- Is AMGN a Buy, Before Earnings?
- Amgen’s Promising Phase 3 Study on Weight Loss Drug Maridebart Cafraglutide
- Amgen’s Tarlatamab Study: A Potential Game-Changer in Lung Cancer Treatment
- Amgen’s AMG 193 Study: A Potential Game-Changer in Thoracic Tumor Treatment